About this Journal Submit a Manuscript Table of Contents
Experimental Diabetes Research
Volume 2007 (2007), Article ID 15803, 6 pages
http://dx.doi.org/10.1155/2007/15803
Research Article

Further Studies on Antioxidant Potential and Protection of Pancreatic β-Cells by Embelia ribes in Experimental Diabetes

Department of Pharmacology, Faculty of Pharmacy, Hamdard University, New Delhi 110062, India

Received 14 July 2006; Revised 10 January 2007; Accepted 20 February 2007

Academic Editor: John Baynes

Copyright © 2007 Uma Bhandari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This study was designed to examine the antioxidant defense by ethanolic extract of Embelia ribes on streptozotocin-(40 mg/kg, intravenously, single-injection) induced diabetes in Wistar rats. Forty days of oral feeding the extract (100 mg/kg and 200 mg/kg) to diabetic rats resulted in significant (P<.01) decrease in blood glucose, blood glycosylated haemoglobin, serum lactate dehydrogenase, creatine kinase, and increase in blood glutathione levels as compared to pathogenic diabetic rats. Further, the extract also significantly (P<.01) decreased the pancreatic thiobarbituric acid-reactive substances (TBARS) levels and significantly (P<.01) increased the superoxide dismutase, catalase, and glutathione levels as compared to above levels in pancreatic tissue of pathogenic diabetic rats. The islets were shrunken in diabetic rats in comparison to normal rats. In the drug-treated diabetic rats, there was expansion of islets. The results of test drug were comparable to gliclazide (25 mg/kg, daily), a standard antihyperglycemic agent. The study concludes that Embelia ribes enhances the antioxidant defense against reactive oxygen species produced under hyperglycemic condition and this protects β-cells against loss, and exhibit antidiabetic property.